the importance of Federal partnerships and investments.

Mr. Chair, I yield 5 minutes to the gentlewoman from California (Ms. Kamlager-Dove).

Much of the written testimony for this hearing focuses on the financial risks and stranded assets.

I would like to highlight for the witnesses and for my fellow Committee members, another type of stranded risk.

Moving forward, Tribes should be exempt from GPRA reporting requirements, so more resources can go directly to services instead of being redirected to data collection, data entry, and data reporting.

I certainly hope that we can find that way back, because a lot of folks support Starbucks because the employees were treated well.

More than 500 family in New Mexico alone, and 65,000 families across the Nation, could lose access to affordable housing over the next 10 years.

We also know that affordable housing is a major challenge, not just in my home State of New Mexico, but really across the Nation.

The budget request for United States Department of Agriculture (USDA) is ambitious, and it includes significant increases across the board.

The programs and activities of this Department affect every single American, from farmers, and rural communities, to children and families who depend on healthy and nutritious food.

Unless we decouple, unless we figure out ways in which we can encourage reinvestment back in these facilities, and continue to provide housing that is affordable for folks, we are going to have a serious problem in communities.

I am pleased that the budget focuses on providing tools to producers in rural communities to address the climate crisis.

This is my first hearing as chairman of this subcommittee, and I am looking forward to a good discussion on the fiscal year 2024 Budget Request for the Department of Agriculture.

I am very concerned about the lack of basic utilities for too many brothers and sisters across the Country.

This sets an incredibly dangerous precedent in terms of both women's reproductive rights but also the FDA's review of drugs.

This judge has replaced his political agenda for the data-driven process used by the FDA.

We should all be concerned because the nature of the epidemic is changing significantly from just the prescription misuse to now cartels driving fentanyl.

The decisions the FDA makes, whether approving a medical device or approving a new drug, must be guided by science and data, not by political pressure.